ArticleJournal of virology2009
Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- How promising are HIV-1-based virus-like particles for medical applications.Frontiers in cellular and infection microbiology · 2022Review
- Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).Journal for immunotherapy of cancer · 2021Article
- Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy.Journal of translational medicine · 2020Article
- Immunological effects of a novel RNA-based adjuvant in liver cancer patients.Cancer immunology, immunotherapy : CII · 2017Article
- Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach.Journal of translational medicine · 2014Article
- Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity.PloS one · 2014Article
- Effects of adjuvants on IgG subclasses elicited by virus-like particles.Journal of translational medicine · 2012Article
- HIV-1 Gag-virus-like particles induce natural killer cell immune responses via activation and maturation of dendritic cells.Journal of innate immunity · 2012Article
- Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.PloS one · 2012Article
- Systems biology applied to vaccine and immunotherapy development.BMC systems biology · 2011Review
- Immunogenomics and systems biology of vaccines.Immunological reviews · 2011Review
- Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.Journal of translational medicine · 2010Article
- Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression.Nutrients · 2010Review
- Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.Journal of translational medicine · 2010Article
- Molecular immune signatures of HIV-1 vaccines in human PBMCs.FEBS letters · 2009Article
- Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs.AIDS research and human retroviruses · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
We have recently shown that human immunodeficiency virus type 1 (HIV-1) Pr55(gag) virus-like particles (HIV-VLPs), produced in a baculovirus expression system and presenting a gp120 molecule from a Ugandan HIV-1 isolate of clade A, induce maturation and activation of monocyte-derived dendritic cells (MDDCs) with a production of Th1- and Th2-specific cytokines. Furthermore, HIV-VLP-loaded MDDCs are able to induce a primary and secondary response in autologous human CD4(+) T cells in an ex vivo immunization assay. In the present study, we show that similar data can be obtained directly with fresh peripheral blood mononuclear cells (PBMCs), and the HIV-1 seropositivity status, with either low or high viremia, does not significantly impair the immune activation status and the responsiveness of circulating monocyte CD14(+) cell populations to an immunogenic stimulus. Some HIV-1-seropositive subjects, however, show a complete lack of maturation induced by HIV-VLPs in CD14(+) circulating cells, which does not consistently correlate with an advanced status of HIV-1 infection. The established Th2 polarization in both HIV-seropositive groups is efficiently boosted by HIV-VLP induction and does not switch into a Th1 pattern, strongly suggesting that specific Th1 adjuvants would be required for therapeutic effectiveness in HIV-1-infected subjects. These results indicate the possibility of screening PBMCs for donor susceptibility to an immunogen treatment, which would greatly simplify the identification of "responsive" vaccinees as well as the understanding of eventual failures in individuals enrolled in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.